Adrenocorticotrophic Hormone
Phase 3Small molecule
Adrenocorticotrophic Hormone is one of 39 small molecule programs targeting Nephrotic Syndrome. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
74 competitors in Nephrotic Syndrome
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Neoral
NovartisApproved
Rayos
RRoxane Laboratories
Approved
Thalitone
Alnylam PharmaceuticalsApproved
Rituxan
RochePhase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Decadron
AAspen Global Incorporated
Approved
Bumex
VValidus Pharmaceuticals
Approved
Cellcept
NovartisPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Ottawa